The company is acquiring fellow gene therapy biotech AavantiBio, fusing together the companies' pipelines and leadership teams, according to an announcement Friday. At the same time, Solid has elected to sell nearly 160 million shares at yesterday's market closing price of 47 cents apiece, generating $75 million in new financing. Aavanti's CEO Bo Cumbo will move across to head up Solid following the acquisition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,